Bio-Rad Laboratories reports Q1 2026 results after the close tomorrow, April 30. The stock is down 8.6% on the week to $279.34, falling harder than most peers. The setup heading into the print is defined by one clear tension: short sellers have rapidly abandoned the trade, yet the stock keeps sliding.
The most striking move this week is in short positioning. Short interest dropped 22% over the past five trading days to 4.5% of free float — a rapid unwind that started sharply on April 23, when shares on loan fell from roughly 1.21 million to under one million in a single session. That reversal is significant. Shorts were building through mid-April, with SI climbing to a near-term high of around 1.28 million shares on April 20. The fact that covering accelerated as the print approached suggests at least some bearish holders chose to take risk off rather than carry a short into an uncertain earnings release. Cost to borrow has followed the same direction, easing to 0.39% — its lowest level in the 30-day window and down 22% on the week — reflecting looser borrow conditions as demand for the stock in the lending market fades. Availability remains ample, and there is no sign of squeeze pressure.
Options traders are not painting a particularly alarmed picture either. The put/call ratio came in at 0.16 on Tuesday, slightly above its 20-day mean of 0.13 but only 0.87 standard deviations away — well within normal range. That's a mild uptick in hedging demand, not a defensive stampede. The 52-week high on PCR is 2.98, which puts the current reading in firmly benign territory. The ORTEX short score has also been declining all week, dropping from 50.7 on April 20 to 44.2 by April 28. Taken together, the lending market, the options market, and the short score are all pointing away from elevated bearish conviction — even as the price action says otherwise.
The Street is cautious but not outright negative. Citigroup's Patrick Donnelly is the most recent and consequential analyst action: on April 7 he downgraded BIO from Buy to Neutral and cut his target from $375 to $300, citing concerns around process chromatography. That move aged quickly — the stock is now trading below his revised target at $279. The remaining consensus is a Hold, with three holders and no outright sells visible. Bulls point to ERP-driven margin improvement and the balance between clinical diagnostics (60% of revenue) and life sciences (40%) as a stabilising factor. Bears are focused on the guidance cut: management flagged a $40 million hit from reduced federal academic and government spending — a more conservative assumption than peers like TMO and AVTR, who guided to 30% and 20% declines respectively in that channel. The EV/EBITDA multiple has contracted about 0.6x over the past 30 days to 16x, reflecting the pressure on forward estimates. One bright spot in the factor scores: the EPS surprise rank comes in at the 97th percentile, meaning the company has a strong history of beating consensus — a detail bulls will lean on heading into tomorrow.
Peers have broadly sold off this week, so BIO's decline is not isolated. TECH dropped 10.3% on the week and TMO fell 10.4%, while AVTR held up better at -7.9% and MTD was the relative outperformer at -4.7%. Bio-Rad's -8.6% lands in the middle of the peer group, suggesting the sector-wide pressure from tariff and funding uncertainty is the dominant driver of the move rather than anything stock-specific.
The last time Bio-Rad reported — Q4 2025 in February — the stock fell 12.6% the next day and was still down 7.4% five days later. The print before that produced a similar 9.4% one-day drop. Two consecutive double-digit negative day-one reactions after earnings is the pattern the Q1 number will be measured against. The key question on the call will be whether management revises its federal funding impact estimate — or whether the $40 million assumption already in guidance proves too conservative compared to what peers are guiding.
See the live data behind this article on ORTEX.
Open BIO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
